<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03667365</url>
  </required_header>
  <id_info>
    <org_study_id>35RC17_8843_ROTAS</org_study_id>
    <secondary_id>2018-A02100-55</secondary_id>
    <nct_id>NCT03667365</nct_id>
  </id_info>
  <brief_title>Randomized Study for the Optimal Treatment of Symptomatic Patients With Low Gradient Severe Aortic Valve Stenosis and Preserved Left Ventricular Ejection Fraction</brief_title>
  <acronym>ROTAS</acronym>
  <official_title>Randomized Study for the Optimal Treatment of Symptomatic Patients With Low Gradient Severe Aortic Valve Stenosis and Preserved Left Ventricular Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to current European Recommendations on valvular heart disease (VHD), &quot;classical&quot;
      severe aortic stenosis (AS) is defined by an aortic valve area (AVA) ≤1 cm2 and indexed AVA
      ≤0.6 cm2/m2, a mean aortic pressure gradient (MAG) &gt;40 mmHg, and a maximal aortic velocity &gt;4
      m/sec.

      Aortic valve replacement (AVR) is recommended (class I indication) in patients with
      &quot;classical&quot; severe AS who have any symptoms related to aortic valve disease.

      In 2007, Hachicha et al. described a particular pattern of severe AS, characterized by an AVA
      ≤0.6 cm2/m2, low mean pressure aortic gradient (MAG &lt;40 mmHg), despite the presence of a
      preserved left ventricular ejection fraction (LVEF ≥50%). This pattern of AS is encountered
      in nearly 15-25 % of patients who have severe AS. Typically, these patients are elderly
      subjects, with several comorbidities, a small left ventricular (LV) cavity with pronounced LV
      concentric remodeling and a restrictive physiology, leading to a decrease in LV stroke volume
      despite a preserved LVEF. The diagnosis and management of patients with low gradient severe
      AS and preserved LVEF are often challenging because:

        1. the presence of a &quot;true&quot; severe aortic stenosis should be carefully confirmed by a
           multi-modality imaging approach;

        2. the best therapeutic management (AVR versus conservative strategy) of symptomatic
           patients with low gradient severe AS and preserved LVEF is not clearly established.

      In very recently updated European guidelines on the management of VHD, symptomatic patients
      with low gradient and low flow severe AS and preserved LVEF have only a class IIa-level C
      indication for AVR. No specific indications are given for the management of symptomatic
      patients with low gradient and normal flow severe AS. This lack of indications is clearly
      attributed to a gap in knowledge which requires further investigations to be filled up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2019</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 19, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time from randomization to first occurrence of any of the components of the composite outcome (adjudicated): all-cause mortality or cardiovascular related hospitalization</measure>
    <time_frame>during 2 years follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of all-cause mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of cardiovascular mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of cardiovascular related hospitalization</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of cerebrovascular events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>walking distance</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
    <description>6-minute walking test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP plasma levels</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life score</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
    <description>test EQ-5D</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>aortic valve replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>strict clinical surveillance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>aortic valve replacement</intervention_name>
    <description>aortic valve replacement surgical or transcatheter aortic valve replacement (will be decided by the heart team before randomization)</description>
    <arm_group_label>aortic valve replacement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>strict clinical surveillance</intervention_name>
    <description>strict clinical surveillance strategy</description>
    <arm_group_label>strict clinical surveillance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18 years

          2. Symptomatic and severe AS defined by an effective AVA ≤1 cm² and indexed AVA ≤0.6
             cm2/m2

          3. LVEF ≥50%

          4. MAG &lt;40 mm Hg (measure confirmed by the multi-window continuous-wave Doppler
             interrogation and use of Pedoff probe)

          5. Confirmation of the presence of severe AS at DSE and MDCT aortic calcium score

          6. Feasibility of AVR by surgery or TAVR according to the &quot;heart team&quot;

          7. Signature of an informed consent

        Exclusion Criteria:

          1. Uncontrolled atrial of ventricular arrhythmias

          2. Patient having a life expectancy &lt;1 year, independently from their aortic pathology

          3. Coronary artery disease necessitating a percutaneous or surgical revascularisation

          4. Presence of a concomitant valve disease needing surgical treatment

          5. Patient who are included in another research protocol

          6. Protected person (adults legally protected (under judicial protection, guardianship or
             supervision), person deprived of their liberty, pregnant woman, lactating woman and
             minor)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena EG Galli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erwan ED Donal, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas NM Mevel</last_name>
    <phone>02 99 28 25 55</phone>
    <email>drc@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne AG Ganivet</last_name>
    <phone>02 99 28 25 55</phone>
    <email>anne.ganivet@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrizio LANCELLOTTI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Amiens - Picardie</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe TRIBOUILLOY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Loïc BIERE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brest - Hôpital La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florent LE VEN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annabelle NGUYEN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dijon - Hôpital François Mitterrand</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Christophe EICHER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augustin COISNE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline VAILLANT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHM - Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilbert HABIB</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique du Millénaire</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine SPORTOUCH -DUKHAN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry LE TOURNEAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena EG GALLI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Saint-Brieuc</name>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magalie DAUDIN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Cardiologique du Nord</name>
      <address>
        <city>Saint-Denis</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien DREYFUS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoan LAVIE-BADIE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Tours - Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne BERNARD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier HUTTIN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Bretagne Atlantique - Site de Vannes</name>
      <address>
        <city>Vannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Michel QUEDILLAC</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>severe aortic valve stenosis</keyword>
  <keyword>low gradient</keyword>
  <keyword>preserved left ventricular ejection fraction</keyword>
  <keyword>symptomatic patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

